1. Middle East Conflict Triggers Stagflation Trading, Global Stock Market Evaporates About $6 Trillion
3. Musk Calls Out OpenAI Chairman Taylor, Links Twitter to 'Far Left' Leadership
4. At Least 13 Domestic Internet Giants Follow OpenClaw, from Cloud Hosting to Mobile System Agent
1. "From Gold to Oil, Hyperliquid has Seized the 'Weekend Pricing Power' of the Financial Market"
The traditional financial market's risk control model relying on physical shutdown time has indeed revealed its limitations. The continuous pricing of risk without waiting for Monday's opening is the core value of offshore exchanges like Hyperliquid. The transfer of market pricing power to the blockchain will be a long process. One should still have dreams, just in case they come true.
Over the past 24 hours, the English-speaking community's discussion has shifted from AI tools and prediction market controversies to the real-world application progress of on-chain infrastructure. Key topics include the flooding of the community with Claude skill documents, the controversy around prediction market valuation and oracle pricing wars, and discussions on AI coding skill leaps. In ecosystem development news, Solana's stablecoin trading volume has hit an all-time high, Coinbase has revealed custody of over 12% of the world's crypto assets, and both the Base payment scenario and Perp DEX trading infrastructure continue to expand.
On-chain fund flow for last week as of March 9

This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.


















Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.











